Cellular Effect
| Cell Line | Activity | Value | Description | Reference |
|---|---|---|---|---|
| HT-29 | CC50 | > 50 μM | Cytotoxicity against human HT-29 cells assessed as reduction in cell viability measured after 8 to 10 hrs by celltiter-glo luminescent cell viability assay | [PMID: 33930803] |
| HT-29 | CC50 | > 50 μM | Cytotoxicity against human HT-29 cells assessed as reduction in cell viability by celltiter-glo luminescent cell viability assay | [PMID: 36288088] |
| HT-29 | EC50 | 0.0036 μM | Anti-necroptotic activity in human HT-29 cells assessed as inhibition of hTNFalpha/Z-VAD-fmk (TSZ)-induced necroptosis by measuring increase in cell viability measured after 8 to 10 hrs by celltiter-glo luminescent cell viability assay | [PMID: 33930803] |
| HT-29 | EC50 | 3.6 nM | Anti-necroptotic activity in TSZ induced human HT-29 cells assessed as increase in cell viability pretreated with compound followed by TSZ stimulation and measured after 16 hrs by celltiter-glo luminescent cell viability assay | [PMID: 36288088] |
| HT-29 | IC50 | 4.1 nM | Induction of necroptosis in human HT-29 cells assessed as increase in TNFalpha/AT-406/zVAD-FMK-induced LDH release preincubated with cells followed by TNFalpha/AT-406/zVAD-FMK addition measured after 16 to 20 hrs by CytoTox 96 nonradioactive cytotoxicity | [PMID: 29485864] |